Although PD-1/PD-L1 inhibitors can be beneficial for patients with dMMR mCRC, immune checkpoint blockade (ICB) monotherapy is ineffective in patients with pMMR.10 Differing from the ICB therapy that restore the existing immunoreaction by targeting the tumor-induced immune deficiency, adoptive cell immunotherapy directly infiltrated into the pMMR mCRC that is considered a “cold tumor”.9,12,20 In the study, patients with pMMR mCRC had significantly survival benefits from the addition of PD1-T cells to chemotherapy. This evidence concerns the gene CD274 and neoplasm.